In order to support the implementation of the health insurance program and as an implementation of the mandate of Permenkes 3 Year 2023 concerning Health Service Tariff Standards, the Ministry of Health has prepared a Minister of Health Decree (KMK) on the Value of Drug Price Claims for the Referral Program, Chronic Disease Drugs at Advanced Health Care Facilities (FPKTL), Chemotherapy Drugs, and Alteplase Drugs.

The KMK is the basis for health care facilities and BPJS in claiming drug prices for health services, where this KMK is prepared by considering various factors, including hospital acquisition prices, other health insurance claim prices, prices resulting from discussions of the National Formulary, electronic catalog prices, prices for raw materials and drug production, and inflation values until 2024.

By setting the claim value of 489 drug items in KMK Number HK.01.07/MENKES/503/2024 on the Claim Value of Drug Prices for the Referral Program, Chronic Disease Drugs at Advanced Health Care Facilities, Chemotherapy Drugs, and Alteplase Drugs on March 20, 2024, the Ministry of Health revoked the previous KMK on claim value, KMK Number HK.01.07/MENKES/1905/2023.

In order to socialize the KMK, the Directorate General of Pharmaceuticals and Health Equipment of the Ministry of Health through the Directorate of Pharmaceutical Production and Distribution held a socialization of the Price Claim Value of the Drug Referral Program, Chronic Disease Drugs in FPKTL, Chemotherapy Drugs, and Alteplase Drugs in a hybrid manner in Jakarta on 18 April 2024.

In her report, Director of Pharmaceutical Production and Distribution Dita Novianti Sugandi conveyed that this socialization activity was attended by representatives of vertical hospitals, public hospitals, health service facilities in collaboration with BPJS, pharmaceutical industry, pharmaceutical and hospital associations, and work units within the Ministry of Health.

"We hope that the KMK dissemination meeting on the value of claims today can provide the same understanding for health service facilities in collaboration with BPJS Health and other relevant stakeholders, not only the provisions listed in KMK Number HK.01.07 / Menkes / 503 / 2024, but how the drug claim mechanism can be implemented in accordance with applicable regulations and can provide benefits in supporting the health insurance program," said Dita.

Director General of Pharmaceutical and Medical Devices, L. Rizka Andalucia in her remarks when officially opening the activity said that the change in KMK claim value was based on the issuance of the latest National Formulary Number HK.01.07/MENKES/2197/2023 on December 28, 2023 which took effect on March 1, 2024.

Furthermore, Rizka said, this KMK change is a form of evaluation by the Government of the previous claim value by considering changes in the price of Drug Raw Materials (BBO), support for products with domestic BBO and drug availability in hard-to-reach areas through changes in regional divisions and delivery frankos to district / city frankos for all regions.

"The Ministry of Health is always committed to ensuring the availability of drugs both in first-level health service facilities and advanced health service facilities, with sufficient types and quantities, evenly distributed of course at affordable prices," said Rizka.